Loading…
DELTIUS is a brand name for Cholecalciferol. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Initial treatment of clinically relevant vitamin D deficiency in adults.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Recommended dose:
One bottle (25 000 IU) weekly. After first month, lower doses may be considered, dependent upon desirable serum levels of 25-hydroxycolecalciferol (25(OH)D), the severity of the disease and the patient´s response to treatment. Alternatively, national posology recommendations in treatment of vitamin D deficiency can be followed.
Special population Dosage in hepatic impairment No dose adjustment is required. Dosage in renal impairment Patients with mild or moderate renal impairment: no specific adjustment is required Colecalciferol must not be used in patients with severe renal impairment.
5 ml oral solution is not recommended in children and adolescents under 18 years of age. 2 Pharmacokinetic properties - “Absorption”). The product should be shaken before use. DELTIUS has a taste of olive oil. DELTIUS can be taken as is from the bottle or to facilitate intake it can also mixed with a small amount of cold or lukewarm food immediately prior to use.
The patient should be sure to take the entire dose. 6 Special precautions for handling and disposal.
Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: uncommon (>1/1,000, <1/100) or rare (>1/10,000, <1/1,000).
Metabolism and nutrition disorders Uncommon:
Hypercalcaemia and hypercalciuria Skin and subcutaneous disorders: Rare: pruritus, rash, and urticaria. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard
Vitamin D3 should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of cholecalciferol is not metabolised normally and other forms of vitamin D have to be used.
Caution is required in patients receiving treatment for cardiovascular disease (see section
1. Hypercalcaemia, hypercalciuria Hypervitaminosis D Kidney stones (nephrolithiasis, nephrocalcinosis) in patients with current chronic hypercalcaemia Severe renal impairment
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Cholecalciferol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.